Anzeige
❌
Mehr »
Sonntag, 18.10.2026 - Börsentäglich über 12.000 News
Über 200% Kurspotenzial, KGV 10: Analysten finden diese Aktie viel zu günstig
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
IM

WKN: A2QCUH | ISIN: SE0014855029 | Ticker-Symbol: 8IM1
Tradegate
15.10.26 | 15:28
5,600 Euro
-2,44 % -0,140
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMPLANTICA AG SDR Chart 1 Jahr
5-Tage-Chart
IMPLANTICA AG SDR 5-Tage-Chart
RealtimeGeldBriefZeit
5,6605,82016.10.
5,6905,79016.10.

Aktuelle News zur IMPLANTICA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.09.Implantica's RefluxStop U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception494VADUZ, Liechtenstein, Sept. 29, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces RefluxStop received an...
► Artikel lesen
11.09.Implantica's Capital Markets Day webcast available on demand429VADUZ, Liechtenstein, Sept. 11, 2026 /PRNewswire/ -- Implantica AG (publ.) would like to thank all who attended its Capital Markets Day in Stockholm on September 9, 2026. A recording of the...
► Artikel lesen
08.09.Implantica to host Capital Markets Day in Stockholm on September 911
25.08.Implantica to host Capital Markets Day in Stockholm on September 9564VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop...
► Artikel lesen
IMPLANTICA Aktie jetzt für 0€ handeln
21.08.Implantica: Umsatz steigt um 66 % - FDA-Zulassung beflügelt Ausblick4
21.08.Implantica: Umsatz steigt um 66 % - FDA-Zulassung beflügelt US-Wachstumsaussichten7
21.08.Implantica AG Q2 Loss Declines4
21.08.Implantica publishes Interim Report January - June 2026 (Q2)595VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop - Strategic Preparation Sets the Stage for Success Significant events in the second quarter of 2026RefluxStop...
► Artikel lesen
21.08.Implantica erhält FDA-Zulassung für Reflux-Implantat RefluxStop6
21.08.Implantica receives FDA approval for GERD implant RefluxStop4
21.08.Implantica receives FDA approval for RefluxStop - Opening the U.S. market683VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S....
► Artikel lesen
14.08.Implantica presents the second quarter (Q2 2026) on August 21 at 15:00 CEST4
10.06.Implantica AG: Bulletin from the Annual General Meeting of Implantica AG248Today, June 10, 2026, the annual general meeting (the "AGM") of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting resolved to adopt all of the board of directors' resolution...
► Artikel lesen
09.06.Implantica announces launch of 20th RefluxStop Center of Excellence in Spain, part of a world-renowned US hospital group431VADUZ, Liechtenstein, June 9, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop...
► Artikel lesen
22.05.Implantica publishes Interim Report January - March 2026 (Q1)638VADUZ, Liechtenstein, May 22, 2026 /PRNewswire/ -- Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStopSignificant events in the first quarter of 2026Secured over...
► Artikel lesen
21.05.Notice of Annual General Meeting of Implantica AG463VADUZ, Liechtenstein, May 21, 2026 /PRNewswire/ -- The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to...
► Artikel lesen
21.05.Implantica announces publication of a new health economics study showing RefluxStop's superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System8
20.05.Implantica submits final response to FDA in the PMA application for RefluxStop for U.S. market approval1.272VADUZ, Liechtenstein, May 20, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including...
► Artikel lesen
19.05.Implantica announces new breakthrough long-term RefluxStop data on severe sufferers presented at DDW 2026970VADUZ, Liechtenstein, May 19, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop...
► Artikel lesen
19.05.IMPLANTICA: RefluxStop gains momentum at DDW 20262
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1